EA200700739A1 - Клостридиальные нейротоксины, применяемые для заживления тканей - Google Patents

Клостридиальные нейротоксины, применяемые для заживления тканей

Info

Publication number
EA200700739A1
EA200700739A1 EA200700739A EA200700739A EA200700739A1 EA 200700739 A1 EA200700739 A1 EA 200700739A1 EA 200700739 A EA200700739 A EA 200700739A EA 200700739 A EA200700739 A EA 200700739A EA 200700739 A1 EA200700739 A1 EA 200700739A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tissue
neurotoxins
injured
treat
clostridial neurotoxins
Prior art date
Application number
EA200700739A
Other languages
English (en)
Inventor
Харолд Виктор Тэйлор
Original Assignee
Мерц Фарма Гмбх Унд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерц Фарма Гмбх Унд Ко. Кгаа filed Critical Мерц Фарма Гмбх Унд Ко. Кгаа
Publication of EA200700739A1 publication Critical patent/EA200700739A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Природные и/или модифицированные нейротоксины Clostridium, включая нейротоксины, не содержащие комплексообразующих белков, которые в природных условиях образуют комплексные соединения с клостридиальными нейротоксинами, применяются для улучшения заживления травмированной поверхности или поверхностной ткани пациента с помощью локального введения в травмированную ткань или в непосредственной близости от нее. Такие нейротоксины могут преимущественно применяться для заживления ран и профилактики формирования рубца и найти применение в области офтальмологии, например в лечении травмированной ткани роговицы, например, с помощью закрытия воспаленных глаз. Другой вариант осуществления включает диагностическое применение для оценки эффективности применения токсина и лекарственные средства для его применения.
EA200700739A 2004-09-27 2005-09-27 Клостридиальные нейротоксины, применяемые для заживления тканей EA200700739A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61339204P 2004-09-27 2004-09-27
PCT/GB2005/003728 WO2006035225A1 (en) 2004-09-27 2005-09-27 Clostridial neurotoxins for use in tissue healing

Publications (1)

Publication Number Publication Date
EA200700739A1 true EA200700739A1 (ru) 2007-10-26

Family

ID=35355850

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700739A EA200700739A1 (ru) 2004-09-27 2005-09-27 Клостридиальные нейротоксины, применяемые для заживления тканей

Country Status (13)

Country Link
US (1) US20060067950A1 (ru)
EP (1) EP1799254A1 (ru)
KR (1) KR20070057862A (ru)
CN (1) CN101027083A (ru)
AU (1) AU2005288758A1 (ru)
BR (1) BRPI0516134A (ru)
CA (1) CA2580122A1 (ru)
EA (1) EA200700739A1 (ru)
IL (1) IL182153A0 (ru)
MX (1) MX2007003407A (ru)
NO (1) NO20072155L (ru)
WO (1) WO2006035225A1 (ru)
ZA (1) ZA200702484B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
WO2015126527A1 (en) * 2014-02-18 2015-08-27 Kaufman-Janette Joely Botulinum neurotoxin for use in the prophylactic treatment of cutaneous wounds
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
WO2018175688A1 (en) * 2017-03-22 2018-09-27 Bonti, Inc. Botulinum neurotoxins for use in therapy
CN107469065B (zh) * 2017-07-19 2021-05-18 广州医科大学 类蛇毒三胜肽在制备用于治疗皮肤溃疡的药物中的应用
US20190183987A1 (en) * 2017-12-18 2019-06-20 Bonti, Inc. Neurotoxins for use in minimizing scarring

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69620888T2 (de) * 1996-11-27 2002-08-14 William J Binder Neurotoxine zur Behandlung von Hauterkrankungen bei Säugetieren
MXPA01004254A (es) * 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders

Also Published As

Publication number Publication date
CN101027083A (zh) 2007-08-29
ZA200702484B (en) 2008-11-26
BRPI0516134A (pt) 2008-08-26
WO2006035225A1 (en) 2006-04-06
IL182153A0 (en) 2007-07-24
EP1799254A1 (en) 2007-06-27
MX2007003407A (es) 2007-05-23
CA2580122A1 (en) 2006-04-06
US20060067950A1 (en) 2006-03-30
AU2005288758A1 (en) 2006-04-06
KR20070057862A (ko) 2007-06-07
NO20072155L (no) 2007-04-26

Similar Documents

Publication Publication Date Title
EA200700739A1 (ru) Клостридиальные нейротоксины, применяемые для заживления тканей
ECSP077328A (es) Neurotoxinas clostridiales para uso en la cicatrización de tejidos
Moffatt et al. Venous leg ulcers: patient concordance with compression therapy and its impact on healing and prevention of recurrence
Jablonka et al. Botulinum toxin to minimize facial scarring
Clarke et al. Strategies aimed at preventing chronic post-surgical pain: comprehensive perioperative pain management after total joint replacement surgery
ES2520765T3 (es) Uso de toxina botulínica para el tratamiento de hiperhidrosis
Murray et al. Guideline for the safe use of hyaluronidase in aesthetic medicine, including modified high-dose protocol
Lalonde Wide-awake extensor indicis proprius to extensor pollicis longus tendon transfer
Imagawa et al. A case of fat injection for treating subcutaneous atrophy caused by local administration of corticosteroid
BRPI0513168A (pt) memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia
Lee et al. Adverse reactions to injectable soft tissue fillers: memorable cases and their clinico-pathological overview
Alshadwi et al. Therapeutic applications of botulinum neurotoxins in head and neck disorders
RU2012110324A (ru) Способы лечения хронического нейрогенного воспаления с помощью модифицированного клостридиального токсина
RU2014103542A (ru) Способы лечения недержания, связанного с половой активностью
RU2013123796A (ru) Способ лечения болезни дюпюитрена
Balcin et al. A comparative study of two methods of surgical treatment for painful neuroma
SE0401182D0 (sv) Novel use of a viscoelastic composition
Cocci et al. How atypical penile curvature influence clinical outcomes in patients with Peyronie's disease receiving collagenase Clostridium histolyticum therapy?
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
Hashemi et al. Effects of ultrasound-guided intraarticular botox vs. corticosteroids for shoulder osteoarthritis
Venus Use of botulinum toxin type A to prevent widening of facial scars
WO2003103699A8 (en) USE OF RAMOPLANIN TO TREAT DISORDERS ASSOCIATED WITH THE TAKING OF ANTIBIOTICS
Rattan et al. Management of ocular adnexal trauma
Aiello et al. A case of palpebral dirofilariasis
Swift et al. Abdominoplasty and abdominal contour surgery: A national plastic surgery survey